Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.62 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.54 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 8/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL29566076 | 0.94 | CRBN (0.64) | OR51E2CRBNFKBP5KDM4EGAA | |
| Caprolactam SCHEMBL5422431 | 0.92 | CRBN (0.61) | OR51E2CRBNFKBP5KDM4EGAA | |
| Trifluoroacetic Acid SCHEMBL27673776 | 0.87 | CRBN (0.55) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL9416189 | 0.85 | OR51E2 (0.71) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL6929736 | 0.84 | OR51E2 (0.79) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL14977562 | 0.84 | OR51E2 (0.79) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL353224 | 0.84 | OR51E2 (0.79) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL14977810 | 0.84 | OR51E2 (0.79) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL4655461 | 0.84 | OR51E2 (0.88) | OR51E2CRBNFKBP5KDM4EGAA | |
| 2-Pyrrolidone SCHEMBL3356160 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349936-B | Super-amphiphilic neutral metal surface roughening treatment liquid and preparation method and application thereof | 株洲绿智新材料科技有限公司 | 2022-01-07 | — | — | CN | claimed |
| CN-111349936-A | Super-amphiphilic neutral metal surface roughening treatment liquid and preparation method and application thereof | 株洲绿智新材料科技有限公司 | 2020-06-30 | — | — | CN | claimed |
| CN-102574869-A | 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives | UCB PHARMA SA | 2012-07-11 | — | — | CN | claimed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| CN-116964046-B | PLK4 inhibitors and uses thereof | 上海齐鲁制药研究中心有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-116964046-A | PLK4 inhibitors and uses thereof | 上海齐鲁制药研究中心有限公司 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022184049-A1 | PLK4 INHIBITOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2022-09-09 | — | — | WO | disclosed |
| CN-110049985-B | Heterocyclic sulfones as ROR gamma modulators | 百时美施贵宝公司 | 2022-05-31 | — | — | CN | disclosed |
| US-11254651-B2 | Histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| CN-111349936-B | Super-amphiphilic neutral metal surface roughening treatment liquid and preparation method and application thereof | 株洲绿智新材料科技有限公司 | 2022-01-07 | — | — | CN | disclosed |
| CN-111349936-A | Super-amphiphilic neutral metal surface roughening treatment liquid and preparation method and application thereof | 株洲绿智新材料科技有限公司 | 2020-06-30 | — | — | CN | disclosed |
| CN-102858159-A | Chemical compounds | GLAXOSMITHKLINE LLC | 2013-01-02 | — | — | CN | disclosed |
| CN-101094847-B | Aryloxy-substituted benzimidazole derivatives | BANYU PHARMA CO LTD | 2011-06-15 | — | — | CN | disclosed |
| US-7829582-B2 | Piperidinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | ELI LILLY AND COMPANY (US) | 2010-11-09 | — | — | US | disclosed |
| CN-101528670-A | 2-hydroxy-1, 3-diaminopropane derivatives | NOVARTIS AG (CH) | 2009-09-09 | — | — | CN | disclosed |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY | 2009-04-02 | — | — | US | disclosed |
| CN-101184488-A | Substituted 4-phenyltetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them | SANOFI AVENTIS DEUTSCHLAND (FR) | 2008-05-21 | — | — | CN | disclosed |
| CN-100364971-C | Pyrrolidin-2-ones as factor Xa inhibitors | GLAXO GROUP LTD (GB) | 2008-01-30 | — | — | CN | disclosed |
| CN-101094847-A | Aryloxy-substituted benzimidazole derivatives | BANYU PHARMA CO LTD (JP) | 2007-12-26 | — | — | CN | disclosed |
| CN-1620434-A | Pyrrolidine-2-ones as factor Xa inhibitors | GLAXO GROUP LTD (GB) | 2005-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254651-B2 | Histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | OR51E2 4368/4885CRBN 1115/4885FKBP5 4825/4885 |
| US-20090088430-A1 | PIERIDINYL SUBSTITUTED PYRROLIDINONES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | HSD11B1, HSD17B1, HSD3B1 | OR51E2 1478/4885CRBN 3451/4885FKBP5 584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.